ADULT ADHD. Attention-deficit hyperactivity disorders
Conditions
Interventions
Intervention 1: The first group that receives Lisdexamfetamine (Vyas) for the treatment of ADHD, which will be continued for 8 weeks for each patient. The low dose of drug will start based on the inte
Sponsors
Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
16 Years to No maximum
Inclusion criteria
Inclusion criteria: Age more than 16 years Diagnosis of adult attention deficit hyperactive disorder based on DSM-5 Diagnosis of adult attention deficit hyperactive disorder based on DIVA-5
Exclusion criteria
Exclusion criteria: Alcohol and other substance us History of Bipolar or psychotic disorders Other psychiatric disorders such as MDD or Autism spectrum disorder Pregnancy or Lactation hypersensitivity to drugs used in this study Neurologic disorders or severe Hepatic or Renal disease BMI less than 18 Dependency to drugs ex. Benzodiazepines MDMA and other substances History of not responding to stimulants Use of any other drug with effects on CNS
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary outcome measure includes changes in scores of BDEFS and WHOQOL scores from the beginning to the end of study. Timepoint: before intervention then 2,4,8 weeks after intervention. Method of measurement: Questioner of Barkley deficits in executive functioning scale for adults , WHO Questioner of quality of life , Clinical global impression GCI Questioner. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAzin Aivazziaei
Tehran University of Medical Sciences
Outcome results
None listed